Clinical Trials at ChinaBio - CT (China Time, GMT+08:00)
China has become a core contributor to global clinical development. As trials move deeper into Phase II/III and global regulatory pathways, delivery quality (not volume) defines speed, credibility, and value. This opening keynote sets the context by examining how China’s clinical ecosystem has matured and what differentiates leading programmes today.
- What has fundamentally changed in China clinical delivery over the past five years?
- Why is China now central, not supplementary, to global development strategies?
- What capabilities differentiate the programmes that consistently deliver globally credible data?
- How are multinational sponsors and Chinese biotechs structuring global development around China?
Designing successful trials in China starts long before execution. From IITs enabling rapid early exploration to sponsor-led global studies requiring regulatory alignment, early decisions now shape speed, feasibility and global success. This session explores how teams design China-ready trials from the outset, and what differentiates programs that successfully scale to global development.
- How are IITs influencing early clinical strategy in China?
- What defines a truly “China-ready” protocol today?
- When should programmes transition from IIT to global development?
- Where do design and regulatory decisions most impact timelines?
- How are leading teams balancing local execution with global requirements?
China offers significant advantages in patient access, experienced investigators and clinical infrastructure. Delivering consistently high-performing trials, however, requires the right operational ecosystem. This session examines how sponsors structure partnerships across CROs, sites and clinical networks to translate China’s scale into reliable recruitment, quality delivery and global confidence.
- What criteria matter most when selecting CRO partners in China today?
- When does a Chinese CRO offer advantages versus a global CRO model?
- How do high-performing programs convert patient access into reliable recruitment?
- What site partnerships and oversight practices consistently improve enrolment and retention?
As China-generated data increasingly supports global regulatory submissions, confidence in quality, traceability and oversight is critical. At the same time, AI is beginning to reshape how trials are designed, monitored and analysed. This session explores how sponsors ensure globally credible data today while also strengthening confidence among global regulators, partners and investors.
- What operational practices most strengthen data quality and inspection readiness?
- What builds regulatory and sponsor confidence in China-generated clinical data?
- Where is AI already delivering measurable value in clinical trial execution?
- Which clinical functions will see the greatest AI impact over the next five years?
- How do global partners and investors evaluate China-generated clinical data when assessing licensing or collaboration opportunities?